These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 10483575

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adjuncts to levodopa therapy: dopamine agonists.
    Poewe W.
    Neurology; 1998 Jun; 50(6 Suppl 6):S23-6; discussion S44-8. PubMed ID: 9633683
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA, Ratkos L, Ondo WG, Jankovic J.
    J Neural Transm (Vienna); 2001 Jun; 108(1):63-70. PubMed ID: 11261747
    [Abstract] [Full Text] [Related]

  • 9. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K, Needleman F, Macphee G, Grosset D.
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL, Roznoski M, Burns RS.
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of Parkinson's disease should begin with a dopamine agonist.
    Montastruc JL.
    Mov Disord; 2000 Mar; 15(2):361-2. PubMed ID: 10752600
    [No Abstract] [Full Text] [Related]

  • 20. Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?
    Coon EA, Laughlin RS.
    J Headache Pain; 2012 Apr; 13(3):255-7. PubMed ID: 22322657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.